Biomarker Assay Validation by Mass Spectrometry.
Carmen Fernández-Metzler1, Brad Ackermann2, Fabio Garofolo3
1PharmaCadence Analytical Services, LLC, 1440 Industry Road, Hatfield, PA, 19940, USA. carmen.fernandez-metzler@PharmaCadence.com.
This study provides recommendations for biomarker assay validation (BAV) using LC-MS, emphasizing fit-for-purpose (FFP) validation tailored to the context of use (COU). These guidelines ensure reliable biomarker data for regulatory submissions.
Area of Science:
- Analytical Chemistry
- Biomarker Discovery and Validation
- Regulatory Science
Background:
- Pharmacokinetic (PK) and toxicokinetic (TK) assay validation is established, with FDA guidance available.
- Biomarker assay validation presents unique challenges, including analyte presence in matrices and reference standard procurement.
- Existing guidance often focuses on challenges rather than specific experimental designs for biomarker assay validation.
Purpose of the Study:
- To provide specific recommendations for biomarker assay validation (BAV) using Liquid Chromatography-Mass Spectrometry (LC-MS).
- To address the unique challenges of validating assays for both small and large molecule biomarkers.
- To promote a fit-for-purpose (FFP) approach to biomarker assay validation, aligning with the context of use (COU).
Main Methods:
- Review and synthesis of existing guidance on bioanalytical method validation (BMV).
- Adaptation of PK assay validation principles to biomarker applications.
- Development of consensus recommendations for biomarker assay validation plan and acceptance criteria.
Main Results:
- Proposed a framework for biomarker assay validation (BAV) emphasizing the context of use (COU).
- Recommended integrating relevant PK assay validation elements into biomarker assay validation.
- Defined specific validation elements and acceptance criteria tailored for biomarker assays, including LC-MS.
Conclusions:
- Biomarker assay validation requires a fit-for-purpose (FFP) strategy, dictated by the assay's context of use (COU).
- A comprehensive validation plan, including COU definition and adapted validation elements, is crucial for reliable biomarker data.
- These recommendations facilitate robust biomarker assay validation for regulatory submissions.
More Related Videos
13:00Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery
Published on: April 17, 2012
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
Related Concept Videos
MALDI-TOF Mass Spectrometry
Matrix-assisted laser desorption ionization (MALDI) is a commonly...
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Mass Spectrometry: Complex Analysis
GC–MS is a powerful hyphenated method commonly used in forensics and environmental...
Mass Spectrometry: Overview
Matrix-Assisted Laser Desorption Ionization (MALDI)
The analyte of interest, a biomolecule or a mixture of biomolecules, is mixed with a suitable matrix material. The...
Mass Spectrometers
